Manufacturing Industry

LILLY (ELI) & COMPANY - Additional Clinical Trial Required for Ruboxistaurin.

PR Newswire UK Disclose, September, 2006

 
Lilly Announces FDA Requirement of Additional Clinical Trial Before 
Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy 
 
Additional Trial Would Take Up To Five Years to Complete; Lilly Currently 
Evaluating Options 
 
INDIANAPOLIS, Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company today 
announced that it is weighing options for the further development of 
ruboxistaurin mesylate in light of a request by the Food and Drug 
Administration (FDA) for an additional, three-year, Phase 3 clinical trial. The 
FDA said it wants additional efficacy data before it will consider approving 
the molecule for the treatment of moderate to severe nonproliferative diabetic 
retinopathy. Lilly believes that such a trial would require up to five years to 
complete....

            
        
    
    	    
                
                
	
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement